TrialBlood advances2022

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.

Catherine C Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.